

VYVGART HYTRULO
(EFGARTIGIMOD AND HYALURONIDASE-QVFC)



PATIENT

Full Name: _____ DOB: _____
 Mobile Phone: _____ Weight: lbs kg
 Allergies: NKDA
Patient status: New to therapy Continuing therapy Last Treatment Date: _____ Next Treatment Date: _____

DIAGNOSIS ICD-10 code (must be specified)

Myasthenia Gravis (gMG) without (acute) exacerbation G70.00 Myasthenia Gravis (gMG) with (acute) exacerbation G70.01
 Chronic inflammatory demyelinating polyneuropathy G61.81

PROVIDER

Provider Name: _____ Provider NPI: _____
 Practice Name: _____ Referral Coordinator Name: _____
 Practice Address: _____
 Phone: _____ Fax: _____ Email: _____

PRE-MEDICATION

Acetaminophen (Tylenol) PO 500 mg 650 mg 1000 mg
 Diphenhydramine (Benadryl) PO IV 25 mg 50 mg
 Methylprednisolone (Solu-Medrol) IV 40 mg 125 mg
 Cetrizine (Zyrtec) 10 mg PO
 Other: _____

THERAPY ADMINISTRATION

Medication	Dose	Frequency
<input type="checkbox"/> Vyvgart Hytrulo (Subcutaneous Injection)	<input type="checkbox"/> 1,008 mg efgartigimod alfa / 11,200 units hyaluronidase	<input type="checkbox"/> Once weekly for 4 weeks (for gMG)
	<input type="checkbox"/> Additional _____ cycles	<input type="checkbox"/> Once weekly (for CIDP)
<small>(Treatment cycles will be given 50 days from the start of the previous treatment cycle.)</small>		
<input checked="" type="checkbox"/> Subcutaneous over approximately 30 to 90 seconds		
<input checked="" type="checkbox"/> Monitor patients for 30 minutes after administration for clinical signs and symptoms of hypersensitivity reactions		
<input checked="" type="checkbox"/> Provide nursing care per Uptiv Health Nursing Procedures, including reaction management and post-procedure observation.		

LABORATORY ORDERS

<input type="checkbox"/> CBC	<input type="checkbox"/> at each dose	<input type="checkbox"/> every _____
<input type="checkbox"/> CMP	<input type="checkbox"/> at each dose	<input type="checkbox"/> every _____
<input type="checkbox"/> CRP	<input type="checkbox"/> at each dose	<input type="checkbox"/> every _____
<input type="checkbox"/> Other _____	<input type="checkbox"/> at each dose	<input type="checkbox"/> every _____

SPECIAL INSTRUCTIONS

PLEASE ATTACH THE FOLLOWING SO WE CAN MOST EFFICIENTLY PROCESS THE PATIENT'S ORDER

Patient Demographics Insurance card Progress Notes supporting DX Positive AchR

Provider Signature _____ Date _____